Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre(R) YeastOne(R) for Candida albicans: a prospective observational cohort study | Zendy

S. J. van Hal | Zendy; S. C.- A. Chen | Zendy; Tania C. Sorrell | Zendy; D. Ellis | Zendy; Monica A. Slavin | Zendy; D. M. Marriott | Zendy

Open Access

Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre(R) YeastOne(R) for Candida albicans: a prospective observational cohort study

Author(s) -

S. J. van Hal,

S. C.- A. Chen,

Tania C. Sorrell,

D. Ellis,

Monica A. Slavin,

D. M. Marriott

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku124

Subject(s) - fluconazole , candida albicans , medicine , univariate analysis , prospective cohort study , corpus albicans , cohort , fungemia , surgery , mycosis , antifungal , microbiology and biotechnology , biology , multivariate analysis , dermatology

Species-specific clinical breakpoints (CBPs) for Candida spp. were established following consideration of clinical outcomes in patients with oesophageal candidiasis. We sought to further determine the validity of the current CBPs based on data from a prospective candidaemia study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research